Core Points - Zentek Ltd. is updating its slate of director nominees for the upcoming annual general and special meeting scheduled for September 25, 2025 [1] Company Updates - The announcement follows a previous news release dated September 3, 2025, indicating ongoing developments within the company [1]

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of debenture units, raising gross proceeds of $2,000,000 through the issuance of 2,000 debenture units [1] Group 1: Offering Details - Each debenture unit consists of $1,000 principal amount of 5% secured convertible debentures and 454 warrants to purchase common shares [2] - The convertible debentures will mature on April 9, 2028, and bear interest at a rate of 5% per annum, payable as a balloon payment on the maturity date [2] - The conversion price for the convertible debentures is set at $2.20 per common share, with the company having the option to force conversion if the trading price exceeds $4.40 [2] Group 2: Security and Warrants - The convertible debentures are secured by the company's interest in 521 mining claims held by its subsidiary Albany Graphite Corp., with a first ranking above all other creditors [3] - A total of 908,000 warrants were issued, each allowing the holder to purchase one common share at the conversion price until the maturity date [4] - The warrants will vest only upon the completion of a sale or transfer of the secured assets to a third party [4] Group 3: Use of Proceeds and Regulatory Approval - Net proceeds from the offering will be utilized for working capital and general corporate purposes [5] - The closing of the offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] Group 4: Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products [7] - The company's patented technology platform, ZenGUARD™, significantly increases bacterial and viral filtration efficiency for surgical masks and aims to enhance HVAC systems [9]

Core Viewpoint - Zentek Ltd. has announced an at-the-market offering agreement to raise up to US$30 million through the sale of common shares in the United States [1][4]. Group 1: Offering Details - The offering will be conducted through an "at-the-market offering" as defined under U.S. Securities Act, with sales made directly on Nasdaq or other recognized marketplaces [3]. - The offering will remain effective until the total gross sales reach US$30 million, unless terminated earlier by any party involved [4]. - Sales will occur at prevailing market prices, which may vary, and net proceeds will be used for corporate purposes as outlined in the Prospectus Supplement [4]. Group 2: Regulatory and Legal Framework - The common shares will be issued under a prospectus supplement dated March 3, 2025, as part of an existing U.S. registration statement [5]. - The offering is being made solely through the Prospectus Supplement, which has been filed with the SEC [5]. - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy securities in jurisdictions where such actions would be unlawful [6]. Group 3: Company Background - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on developing and commercializing innovative products [7]. - The company’s patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8]. - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University, aimed at diagnostic and therapeutic markets [9].

Core Viewpoint - Zentek has provided an update on its ZenGUARD(TM) enhanced air filters, specifically targeting the Canadian market, highlighting advancements in technology and market strategy [1] Group 1: Product Development - ZenGUARD(TM) air filters utilize a patented technology that enhances air quality by capturing and neutralizing airborne pathogens [1] - The filters are designed to be compatible with existing HVAC systems, making them an attractive option for various commercial and residential applications [1] Group 2: Market Strategy - The company is focusing on expanding its presence in the Canadian market, leveraging partnerships with local distributors to enhance market penetration [1] - Zentek aims to address the growing demand for improved air quality solutions, particularly in light of increased awareness surrounding health and safety in indoor environments [1] Group 3: Financial Implications - The introduction of ZenGUARD(TM) is expected to contribute positively to the company's revenue streams, as the demand for air filtration solutions continues to rise [1] - Zentek is positioning itself to capitalize on government initiatives and funding aimed at improving public health through better air quality [1]

Core Points - Zentek Ltd. announced the voting results from its annual and special meeting of shareholders held on September 26, 2024, with all resolutions being approved by shareholders [3]. - The election results for the board of directors showed high approval rates for all nominees, with Lisa Sim receiving the highest at 98.638% [4]. - Shareholders approved the appointment of BDO Canada LLP as auditors with a significant majority of 99.275% [5]. - The omnibus long-term incentive plan was also approved, receiving 82.077% votes in favor [5]. Company Overview - Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products aimed at enhancing the competitiveness of its commercial partners [6]. - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to improve viral filtration efficiency for surgical masks and HVAC systems [7].

● . . Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency September 13, 2024 4:45 PM EDT | Source: Zentek Ltd. Guelph, Ontario--(Newsfile Corp. - September 13, 2024) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company") announces that on September 11, 2024, it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of t ...

Core Points - Zentek Ltd. has successfully closed a non-brokered private placement of units, raising gross proceeds of $3,069,950 through the issuance of 2,361,500 units at a price of $1.30 per unit [2][3] - The net proceeds from the offering will be allocated for working capital and general corporate purposes, supporting the company's international market expansion strategy [3][4] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $3.00 for a period of 24 months [3][4] Financial Details - The cash commission paid to eligible persons in connection with the offering totaled $29,499.40 [4] - The offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [4] Company Overview - Zentek is an intellectual property development and commercialization company focused on creating novel products that enhance the safety and sustainability of commercial partners' offerings [6] - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to improve viral filtration efficiency in HVAC systems [7]

Core Points - Zentek Ltd. has announced an upsized non-brokered private placement of units, increasing the offering to 2,361,538 units at a price of $1.30 per unit, resulting in aggregate gross proceeds of up to $3,070,000 [2][3] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [3] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $3.00 for a period of 24 months from the closing date [3] Additional Information - The company may pay a cash commission of 5% of the gross proceeds to eligible finders who introduce subscribers to the offering [4] - The closing of the offering is contingent upon receiving all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [5] Company Overview - Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products aimed at providing competitive advantages to commercial partners [7] - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to enhance viral filtration efficiency for surgical masks and HVAC systems [8]

Company Overview - Zentek Ltd. is an intellectual property development and commercialization company focused on research, development, and commercialization of novel products aimed at providing commercial partners with a competitive advantage by enhancing product quality, safety, and environmental sustainability [13]. Technology and Product Development - Zentek's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and significantly improves viral filtration efficiency for surgical masks, with plans to extend this capability to HVAC systems [1]. Financial Activities - The company has announced a non-brokered private placement of units for up to $3 million, issuing up to 2,307,692 units at a price of $1.30 per unit. The gross proceeds will be allocated for working capital and general corporate purposes [6]. - Each unit consists of one common share and one-half of one common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $3.00 for a period of 24 months from the closing date of the offering [14]. Regulatory Compliance - The closing of the offering is contingent upon receiving all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [12].